Filing Flows › Myriad Genetics (MYGN) › Q3 2026 › vs Q3 2025
Myriad Genetics (MYGN) Q3 2026 vs Q3 2025 (year over year)
Myriad Genetics's revenue fell $3.0M (-1%) from $206M in Q3 2025 to $203M in Q3 2026. The biggest changes: Prenatal Health −$5.2M (-12%); Cancer Care Continuum +$1.4M (+1%); Mental Health +$800K (+2%).
Myriad Genetics, Q3 2026: revenue $203M (-2% year over year), operating margin -19.7%, net loss $43.9M, operating cash flow −$6.5M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Cancer Care Continuum | $124M | $122M | $1.4M | +1% |
| Mental Health | $39.5M | $38.7M | $800K | +2% |
| Prenatal Health | $39.3M | $44.5M | −$5.2M | -12% |
| Revenue | $203M | $206M | −$3.0M | -1% |
| Net loss | $43.9M | $27.4M | $16.5M | +60% |
| Costs & expenses | $247M | $233M | $13.5M | +6% |
| Operating costs | $243M | $229M | $13.6M | +6% |
| Interest & other, net | $3.7M | $2.9M | $800K | +28% |
| Income tax | $300K | $1.2M | −$900K | -75% |
| Cost of revenue | $65.0M | $61.9M | $3.1M | +5% |
| Research & development | $26.5M | $28.2M | −$1.7M | -6% |
| Sales & marketing | $83.9M | $71.0M | $12.9M | +18% |
| General & admin | $67.2M | $67.9M | −$700K | -1% |
| Operating cash sources | $43.9M | $27.4M | $16.5M | +60% |
| Depreciation & amortization | $12.6M | $12.6M | $0 | 0% |
| Share-based compensation | $9.2M | $12.2M | −$3.0M | -25% |
| Working capital & other | $15.6M | $23.7M | −$8.1M | -34% |
| Cash used in operations | $6.5M | −$21.1M | $27.6M | — |
| Net loss absorbed | $43.9M | $27.4M | $16.5M | +60% |
Questions
How much did Myriad Genetics's revenue grow year over year in Q3 2026?
Myriad Genetics's revenue fell $3.0M (-1%) from $206M in Q3 2025 to $203M in Q3 2026.
What drove Myriad Genetics's revenue change in Q3 2026?
Prenatal Health −$5.2M (-12%); Cancer Care Continuum +$1.4M (+1%); Mental Health +$800K (+2%).